361 related articles for article (PubMed ID: 26550910)
1. Photodynamic therapy for basal cell carcinoma.
Fargnoli MC; Peris K
Future Oncol; 2015 Nov; 11(22):2991-6. PubMed ID: 26550910
[TBL] [Abstract][Full Text] [Related]
2. Urticaria after methyl aminolevulinate photodynamic therapy in a patient with nevoid basal cell carcinoma syndrome.
Wolfe CM; Green WH; Hatfield HK; Cognetta AB
J Drugs Dermatol; 2012 Nov; 11(11):1364-5. PubMed ID: 23135091
[TBL] [Abstract][Full Text] [Related]
3. Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: a single blind, non-inferiority, randomised controlled trial.
Arits AH; Mosterd K; Essers BA; Spoorenberg E; Sommer A; De Rooij MJ; van Pelt HP; Quaedvlieg PJ; Krekels GA; van Neer PA; Rijzewijk JJ; van Geest AJ; Steijlen PM; Nelemans PJ; Kelleners-Smeets NW
Lancet Oncol; 2013 Jun; 14(7):647-54. PubMed ID: 23683751
[TBL] [Abstract][Full Text] [Related]
4. Reflectance confocal microscopy allows in vivo real-time noninvasive assessment of the outcome of methyl aminolaevulinate photodynamic therapy of basal cell carcinoma.
Venturini M; Sala R; Gonzàlez S; Calzavara-Pinton PG
Br J Dermatol; 2013 Jan; 168(1):99-105. PubMed ID: 23013443
[TBL] [Abstract][Full Text] [Related]
5. Photodynamic therapy for basal cell carcinomas in organ-transplant recipients.
Guleng GE; Helsing P
Clin Exp Dermatol; 2012 Jun; 37(4):367-9. PubMed ID: 22420420
[TBL] [Abstract][Full Text] [Related]
6. Photodynamic therapy with methyl aminolevulinate for primary nodular basal cell carcinoma: results of two randomized studies.
Foley P; Freeman M; Menter A; Siller G; El-Azhary RA; Gebauer K; Lowe NJ; Jarratt MT; Murrell DF; Rich P; Pariser DM; Oseroff AR; Barnetson R; Anderson C; Kossard S; Gibson LE; Tope WD
Int J Dermatol; 2009 Nov; 48(11):1236-45. PubMed ID: 20064185
[TBL] [Abstract][Full Text] [Related]
7. delta-Aminolevulinic acid and blue light photodynamic therapy for treatment of multiple basal cell carcinomas in two patients with nevoid basal cell carcinoma syndrome.
Itkin A; Gilchrest BA
Dermatol Surg; 2004 Jul; 30(7):1054-61. PubMed ID: 15209801
[TBL] [Abstract][Full Text] [Related]
8. Long-Term Efficacy of Photodynamic Therapy with Fractionated 5-Aminolevulinic Acid 20% versus Conventional Two-Stage Topical Methyl Aminolevulinate for Superficial Basal-Cell Carcinoma.
van Delft LCJ; Nelemans PJ; Kessels JPHM; Kreukels H; Roozeboom MH; de Rooij MJM; Mosterd K; de Haas ERM; Kelleners-Smeets NWJ
Dermatology; 2022; 238(6):1044-1049. PubMed ID: 35598594
[TBL] [Abstract][Full Text] [Related]
9. Tumor thickness and adnexal extension of superficial basal cell carcinoma (sBCC) as determinants of treatment failure for methylaminolevulinate (MAL)-photodynamic therapy (PDT), imiquimod, and 5-fluorouracil (FU).
Roozeboom MH; van Kleef L; Arits AH; Mosterd K; Winnepenninckx VJ; van Marion AM; Nelemans PJ; Kelleners-Smeets NW
J Am Acad Dermatol; 2015 Jul; 73(1):93-8. PubMed ID: 25935596
[TBL] [Abstract][Full Text] [Related]
10. Similar effectiveness of methyl aminolevulinate and 5-aminolevulinate in topical photodynamic therapy for nodular basal cell carcinoma.
Kuijpers DI; Thissen MR; Thissen CA; Neumann MH
J Drugs Dermatol; 2006; 5(7):642-5. PubMed ID: 16865869
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of photodynamic therapy with methyl aminolevulinate in the treatment of superficial and nodular basal cell carcinoma: an open-label trial.
Surrenti T; De Angelis L; Di Cesare A; Fargnoli MC; Peris K
Eur J Dermatol; 2007; 17(5):412-5. PubMed ID: 17673385
[TBL] [Abstract][Full Text] [Related]
12. Methyl aminolevulinate-photodynamic therapy for basal cell carcinoma.
Szeimies RM
Dermatol Clin; 2007 Jan; 25(1):89-94. PubMed ID: 17126746
[TBL] [Abstract][Full Text] [Related]
13. Photodynamic therapy with methyl-5-aminolevulinate for basal cell carcinoma: A systematic review and meta-analysis.
Wang BC; Fu C; Qin L; Zeng XY; Liu Q
Photodiagnosis Photodyn Ther; 2020 Mar; 29():101667. PubMed ID: 31978564
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of topical imiquimod and fluorouracil vs. photodynamic therapy for treatment of superficial basal-cell carcinoma.
Arits AH; Spoorenberg E; Mosterd K; Nelemans P; Kelleners-Smeets NW; Essers BA
Br J Dermatol; 2014 Dec; 171(6):1501-7. PubMed ID: 24749843
[TBL] [Abstract][Full Text] [Related]
15. The use of photodynamic therapy in dermatology: results of a consensus conference.
Nestor MS; Gold MH; Kauvar AN; Taub AF; Geronemus RG; Ritvo EC; Goldman MP; Gilbert DJ; Richey DF; Alster TS; Anderson RR; Bank DE; Carruthers A; Carruthers J; Goldberg DJ; Hanke CW; Lowe NJ; Pariser DM; Rigel DS; Robins P; Spencer JM; Zelickson BD
J Drugs Dermatol; 2006 Feb; 5(2):140-54. PubMed ID: 16485882
[TBL] [Abstract][Full Text] [Related]
16. A 10-year follow-up on the chemopreventive role of photodynamic therapy in a Gorlin syndrome patient.
Thompson A; Mattia A; Green WH; Cognetta AB
Australas J Dermatol; 2022 Nov; 63(4):e378-e379. PubMed ID: 36222440
[No Abstract] [Full Text] [Related]
17. Blue light versus red light for photodynamic therapy of basal cell carcinoma in patients with Gorlin syndrome: A bilaterally controlled comparison study.
Maytin EV; Kaw U; Ilyas M; Mack JA; Hu B
Photodiagnosis Photodyn Ther; 2018 Jun; 22():7-13. PubMed ID: 29471147
[TBL] [Abstract][Full Text] [Related]
18. Fractionated 5-aminolevulinic acid photodynamic therapy after partial debulking versus surgical excision for nodular basal cell carcinoma: a randomized controlled trial with at least 5-year follow-up.
Roozeboom MH; Aardoom MA; Nelemans PJ; Thissen MR; Kelleners-Smeets NW; Kuijpers DI; Mosterd K
J Am Acad Dermatol; 2013 Aug; 69(2):280-7. PubMed ID: 23566914
[TBL] [Abstract][Full Text] [Related]
19. Photodynamic therapy using methyl aminolevulinate in the management of primary superficial basal cell carcinoma: clinical and health economic outcomes.
Caekelbergh K; Nikkels AF; Leroy B; Verhaeghe E; Lamotte M; Vincent R
J Drugs Dermatol; 2009 Nov; 8(11):992-6. PubMed ID: 19894366
[TBL] [Abstract][Full Text] [Related]
20. Clinical investigation of the novel iron-chelating agent, CP94, to enhance topical photodynamic therapy of nodular basal cell carcinoma.
Campbell SM; Morton CA; Alyahya R; Horton S; Pye A; Curnow A
Br J Dermatol; 2008 Aug; 159(2):387-93. PubMed ID: 18544077
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
